Trade Equillium, Inc. - EQ CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0167 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.4479 |
| Open | 0.4171 |
| 1-Year Change | -75.58% |
| Day's Range | 0.4171 - 0.4494 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 0.4479 | 0.0181 | 4.21% | 0.4298 | 0.4571 | 0.4278 |
| Apr 23, 2025 | 0.4689 | 0.0109 | 2.38% | 0.4580 | 0.4689 | 0.4580 |
| Apr 22, 2025 | 0.4478 | 0.0000 | 0.00% | 0.4478 | 0.4478 | 0.4478 |
| Apr 16, 2025 | 0.4232 | 0.0020 | 0.47% | 0.4212 | 0.4250 | 0.4212 |
| Apr 15, 2025 | 0.4371 | 0.0093 | 2.17% | 0.4278 | 0.4371 | 0.4278 |
| Apr 14, 2025 | 0.4478 | -0.0300 | -6.28% | 0.4778 | 0.4878 | 0.4378 |
| Apr 11, 2025 | 0.4466 | -0.0062 | -1.37% | 0.4528 | 0.4878 | 0.4078 |
| Apr 10, 2025 | 0.4518 | -0.0029 | -0.64% | 0.4547 | 0.4584 | 0.4171 |
| Apr 9, 2025 | 0.4331 | -0.0147 | -3.28% | 0.4478 | 0.4487 | 0.4257 |
| Apr 8, 2025 | 0.4678 | 0.0188 | 4.19% | 0.4490 | 0.4678 | 0.4490 |
| Apr 7, 2025 | 0.4659 | 0.0681 | 17.12% | 0.3978 | 0.4659 | 0.3978 |
| Apr 4, 2025 | 0.4766 | 0.0048 | 1.02% | 0.4718 | 0.4766 | 0.4718 |
| Apr 3, 2025 | 0.4878 | -0.0295 | -5.70% | 0.5173 | 0.5224 | 0.4878 |
| Apr 2, 2025 | 0.4878 | 0.0537 | 12.37% | 0.4341 | 0.4978 | 0.4341 |
| Apr 1, 2025 | 0.5178 | 0.1100 | 26.97% | 0.4078 | 0.5457 | 0.4078 |
| Mar 31, 2025 | 0.3901 | -0.0077 | -1.94% | 0.3978 | 0.4070 | 0.3578 |
| Mar 28, 2025 | 0.4032 | -0.0346 | -7.90% | 0.4378 | 0.4378 | 0.3782 |
| Mar 27, 2025 | 0.4079 | -0.0911 | -18.26% | 0.4990 | 0.5713 | 0.4079 |
| Mar 26, 2025 | 0.7404 | -0.0474 | -6.02% | 0.7878 | 0.7878 | 0.7049 |
| Mar 25, 2025 | 0.7628 | -0.0350 | -4.39% | 0.7978 | 0.8079 | 0.7628 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Equillium, Inc. Company profile
About Equillium Inc
Equillium, Inc. is a clinical-stage biotechnology company. The Company develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The Company's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The Company's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. It also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Equillium Inc revenues was not reported. Net loss increased 31% to $39.1M. Higher net loss reflects Research and development - Balancing val increase of 30% to $24.4M (expense), General and administrative - Balancing increase of 11% to $9M (expense), Other expense, net decrease from $358K (income) to $250K (expense).
| Industry: | Pharmaceuticals (NEC) |
2223 Avenida de La Playa Ste 105
LA JOLLA
CALIFORNIA 92037-3217
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com